← Back to Search

Ketamine Hydrochloride for Opioid Use Disorder

Phase 2
Waitlist Available
Led By Jennifer Jones, MD
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up outcomes will be cumulatively assessed from the time that the first participant is screened through the time that the last participant is enrolled. estimated time frame of: 23 months.
Awards & highlights

Study Summary

This trial is examining whether ketamine could improve treatment outcomes for people with opioid addiction and depression when used with buprenorphine. If you enroll, participation will last about 8 weeks.

Eligible Conditions
  • Opioid Use Disorder
  • Depression
  • Opioid Addiction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~outcomes will be cumulatively assessed from the time that the first participant is screened through the time that the last participant is enrolled. estimated time frame of: 23 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and outcomes will be cumulatively assessed from the time that the first participant is screened through the time that the last participant is enrolled. estimated time frame of: 23 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Individuals Completing Informed Consent
Percentage of Individuals Completing the Full Protocol
Secondary outcome measures
Change in Depression Severity

Side effects data

From 2020 Phase 4 trial • 75 Patients • NCT03156504
1%
Lightheadedness with low blood pressure
1%
Pump Malfunction
1%
PTSD
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ketamine

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Group A (Ketamine)Experimental Treatment1 Intervention
Group II: Group B (Placebo)Placebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine Hydrochloride
2018
Completed Phase 4
~1000

Find a Location

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
940 Previous Clinical Trials
7,396,943 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,485 Previous Clinical Trials
2,622,359 Total Patients Enrolled
Jennifer Jones, MDPrincipal Investigator - Medical University of South Carolina
Texas Health Harris Methodist Continued Care Hospital, Texas Health Harris Methodist Heart Center
Medical University Of South Carolina College Of Medicine (Medical School)
~5 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top